Now this comment may polarise a few of you, but personally I do not rate SC as the person who will (or is best placed to) take SUD to the next level. We really need a heavy hitter and someone with substantially more experience around corporate strategies, managerial skills and network contacts. If only someone like Brian Mcnamee was available (but that would just be wishful thinking, but we do have a product that will help save millions of lives due to one of the biggest global diseases). The board needs to be strengthened with one or two real biotech/pharma industry stalwarts or someone with strong international political/government contacts. The market would really sit up and take real notice of Suda.
GolfR
December deal, page-36
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.025(15.6%) |
Mkt cap ! $194.5M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 19.0¢ | 16.0¢ | $1.303M | 7.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 167000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 349887 | 3 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |